CHEK2 and cancer: SBS3, the HRD-related mutational signature (17), was observed to some level in 13% (2/16) of CHEK2-deficient cancers, and it was the predominant mutational signature (86%, 24/28) in the BRCA1/2-deficient group (P < .001; Figure 1, D).